Skip to content Skip to sidebar Skip to footer
Subscribe Now
Viewpoints_Mathew L. Sherman
VIEWPOINTS

PharmaShots Interview: Deciphera’s Mathew L. Sherman Shares Insight on Data of QINLOCK and DCC-3014 Presented at CTOS 2020

In an interview with PharmaShots, Matthew L. Sherman, M.D., Executive Vice President and Chief Medical Officer of Deciphera shed light on encouraging preliminary results from the ongoing P-I/II study of DCC-3014 in TGCT patients and also presented the data of QINLOCK at CTOS 2020Shots:Deciphera presented encouraging preliminary results from the ongoing Phase 1/2 study of DCC-3014 in tenosynovial giant cell tumor…
February 17, 20210Comments

Read more

Viewpoints_Bradley Galer
VIEWPOINTS

PharmaShots Interview: Zogenix’s Bradley Galer Shares Insight on Fintepla (fenfluramine, oral solution)

In an interview with PharmaShots, Bradley Galer, M.D., Chief Medical Officer at Zogenix shed light on data supporting the regulatory application and what the EU approval of Fintepla will mean in terms of reducing the high physical, emotional, and financial burden associated with the disease.Shots:Fintepla was approved by the EC in Dec'2020 as a new add-on therapy to…
February 16, 20210Comments

Read more

Viewpoints_Nathalie Landry
VIEWPOINTS

PharmaShots Interview: Medicago’s Nathalie Landry Shares Insight on Plant-Derived Vaccine for COVID-19

In an interview with PharmaShots, Nathalie Landry, Executive Vice President, Scientific and Medical Affairs at Medicago shared her views on positive results of P-I clinical trial results for its plant-derived COVID-19 vaccine. Shots:The results of the trial demonstrated that 100% of participants developed a promising antibody response after two doses of Medicago's COVID-19 adjuvanted vaccine candidateThe vaccine…
February 15, 20210Comments

Read more

Biopharma Deal Terminations Top 20 2020
TOP 20

Top 20 Biopharma Deal Terminations of 2020 Based on Total Deal Value

The biopharma industry saw numerous deal terminations in 2020. Clinical and regulatory results- change in control limitations- and strategic reprioritizations were among the most common reasons for deal termination.Sanofi and Hanmi's agreement in 2015 ranked first under which Hanmi regained WW rights to its protein/peptide discovery technology- lapscovery. The second position goes to the…
February 11, 20210Comments

Read more

Viewpoints_Andreas Harstrick
VIEWPOINTS

PharmaShots Interview: Affimed’s Andreas Harstrick Shares Insight on AFM13 and its Data Presented at ASH 2020

In an interview with PharmaShots, Dr. Andreas Harstrick, Chief Medical Officer at Affimed shared his views on updated clinical data related to their lead innate cell engager AFM13 at the virtual 62nd American Society of Hematology (ASH) annual meeting.Shots:The study showed an ORR of 42% (6/14 patients) and demonstrated clinical activity in two…
February 10, 20210Comments

Read more

Viewpoints_Duncan Short
VIEWPOINTS

PharmaShots Interview: ViiV Healthcare’s Duncan Short Shares Insight on PROgress Study Demonstrating that Pre-Visit Survey Can Improve HIV Care

In a recent interview with PharmaShots, Duncan Short, Ph.D., Director of Global Implementation Science at ViiV Healthcare shared his views on the findings of a new study demonstrating how the inclusion of a brief survey focused on patient-reported outcomes (PROs) during doctor's appointments can improve HIV care.Shots:In the study, people living with HIV were provided…
February 8, 20210Comments

Read more

Viewpoints_Edouard Gasser
VIEWPOINTS

PharmaShots Interview: Tilak Healthcare’s Edouard Gasser Shares Insights on OdySight

In a recent interview with PharmaShots, Edouard Gasser, CEO of Tilak Healthcare shared his views on OdySight, which is the first medical game to monitor eyesight for patients with chronic eye diseases.Shots:OdySight is a free mobile game and medical-grade application used to remotely monitor patients suffering from chronic maculopathies such as AMD, macular edema, and diabetic retinopathy…
February 4, 20210Comments

Read more